Nature Communications, noted British journal, shares results of “Estudo Advento” research

The relationship between a specific intestinal bacteria and its possible effects on controlling diabetes was published in an international scientific article, featuring the dietary habits of Seventh-day Adventists in Brazil.

“Estudo Advento” or Advent Study was published on November 14 in the highly regarded scientific journal Nature Communications, which is part of the Nature publishing group. The British journal is considered one of the few academic journals that publishes original research in several scientific fields, and has an online audience of 3 million readers monthly.

The article was written by Brazilian researchers Ana Carolina de Moares, Gabriel R. Fernandes, Alexandre C. Pereira, Sandra R. G. Ferreira, and Seventh-day Adventist physician Everton Padilha Gomes, who was the coordinator of the study, in partnership with scientists from Oregon State University in the United States.

According to Ana Carolina de Moares, who holds a doctorate in public health nutrition from the University of São Paulo (USP), this is only one in a series of articles based on the diets of selected Seventh-day Adventists in São Paulo.

The nutritionist explained the content published in Nature Communications identified a relationship between the immune system and bacteria in the intestines and glucose metabolism. It was discovered that there is a difference in the quantity of Akkermansia muciniphila bacteria in the intestines of people with diabetes, those diagnosed with pre-diabetes, and those who have “normotolerants” or normal glucose metabolism.

“These bacteria are shown to be present in people with diabetes and type 2 diabetes,” de Moares said.

A relationship between the Adventist diet and the presence of the bacteria has yet to be established.

For the creation of this report, 94 Brazilian Adventists between the ages of 35-65 were evaluated. They also participated in the larger group that was included in the Advent Study, which involved more than 1,500 people.

Results in mice

Akkermansia muciniphila bacteria has been studied globally for several years. One of the studies, developed by scientists from the University of Louvain, in Belgium, used the bacteria as a probiotic with the purpose of reducing the weight and the risk of diabetes type 2 in mice. They noticed the bacteria can alter the layer of mucus that surrounded the intestines, protecting it against the development of diabetes type 2.

During the experiment, the mice were given a diet rich in fat, resulting in weight gain. Later, they received doses of the bacteria and lost half the weight they gained without any dietary change.

The mice treated with the bacteria also showed a low resistance level to the insulin hormone, intolerance of which is a classic symptom of type 2 diabetes.

The Nature Communications article’s data could help create a means for this type of testing to take place with humans, which could in turn measure the presence of the bacteria among those who are vegetarians, lacto-ovo vegetarian or omnivorous.


As the oldest publishing platform of the Seventh-day Adventist Church, the Adventist Review (est. 1849) provides inspiration and information to the global church through a variety of media, including print, websites, apps, and audio and video platforms.Content appearing on any of the Adventist Review platforms has been selected because it is deemed useful to the purposes and mission of the journal to inform, educate, and inspire the denomination it serves.Unless identified as created by “Adventist Review” or a designated member of the Adventist Review staff, content is assumed to express the viewpoints of the author or creator of the content.

We reserve the right to approve and disapprove comments accordingly and will not be able to respond to inquiries regarding that. Please keep all comments respectful and courteous to authors and fellow readers.



Source link

CategoryNews
Write a comment:

Leave a Reply

This site uses Akismet to reduce spam. Learn how your comment data is processed.

© 2019 Bethanië Church all rights reserved.

Follow us: